
Methylene Blue
Methylene blue is an approved injection for methemoglobinemia, given in hospital. Taking it by mouth for focus, memory, mood or longevity is not an approved use: human evidence is limited to a few small trials, including a single-dose brain-scan study in 26 healthy adults and small studies in bipolar depression, and a large trial of a related compound in Alzheimer's disease was negative. It carries a boxed warning for serotonin syndrome with antidepressants and opioids, and it can destroy red blood cells in G6PD deficiency.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults and children with acquired methemoglobinemia, treated with the intravenous product by a healthcare provider
Common dosing range
Your prescriber sets the dose. The ProvayBlue label: 1 mg/kg intravenously over 5 to 30 minutes, with one repeat dose of up to 1 mg/kg an hour later if needed. There is no approved oral dose
When to expect effects
In the label's studies, 26 of 28 adults had methemoglobin cut by at least half at the first check after treatment (median 2.7 hours after the infusion)
Watch out for
Boxed warning: serious or fatal serotonin syndrome when used with SSRIs, SNRIs, MAOIs and opioids. Contraindicated in G6PD deficiency (risk of severe hemolytic anemia) and in severe allergy to methylene blue or other thiazine dyes. Oral products sold online are not FDA-approved and their strength and purity are unverified
What is it
Methylene blue (methylthioninium chloride) is a blue dye that is also a prescription medicine. In the US it is FDA-approved only as an injection into a vein: ProvayBlue and generic methylene blue injections treat acquired methemoglobinemia, a condition in which too much hemoglobin is changed into a form that cannot carry oxygen, in adults and children. A healthcare provider gives it, usually in a hospital. Every methylene blue approval listed in Drugs@FDA (checked November 2026) is an intravenous solution. The drops, capsules and powders sold online as a "biohacking", brain or energy supplement are not FDA-approved drugs. It also appears in some older urinary antiseptic tablets (for example Urelle and Uribel), which DailyMed lists as "unapproved drug other".
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Alzheimer's disease (LMTM, a related compound, not methylene blue itself) Good Evidence | None on the main measures of the largest completed trial | Not established | Measured over 15 months |
bipolar depression, added to other treatment (off-label) Limited Evidence | Moderate improvement in depression and anxiety scores in small trials | Adults with bipolar disorder on mood stabilizers, under specialist care | Months; measured over 6 months to 2 years |
delirium after surgery in older adults (off-label, intravenous) Limited Evidence | Large in one trial; delirium 8.3% vs 20.4% | Older adults having joint replacement under anesthesia | Measured over 5 days after surgery |
memory and attention in healthy adults (off-label) Mixed Evidence | Small; 7% more correct answers on one memory task, plus changes in brain-scan activity | Healthy adults in a laboratory study | Measured 1 hour after a single dose |
fear extinction in claustrophobia and PTSD therapy (off-label) Mixed Evidence | Mixed; helped only when therapy sessions went well, and possibly harmful when they did not | Adults in exposure-based therapy within a research setting | Measured 1 to 3 months after brief therapy |
Alzheimer's disease (LMTM, a related compound, not methylene blue itself)
- Effect
- None on the main measures of the largest completed trial
- Best fit
- Not established
- Time
- Measured over 15 months
bipolar depression, added to other treatment (off-label)
- Effect
- Moderate improvement in depression and anxiety scores in small trials
- Best fit
- Adults with bipolar disorder on mood stabilizers, under specialist care
- Time
- Months; measured over 6 months to 2 years
delirium after surgery in older adults (off-label, intravenous)
- Effect
- Large in one trial; delirium 8.3% vs 20.4%
- Best fit
- Older adults having joint replacement under anesthesia
- Time
- Measured over 5 days after surgery
memory and attention in healthy adults (off-label)
- Effect
- Small; 7% more correct answers on one memory task, plus changes in brain-scan activity
- Best fit
- Healthy adults in a laboratory study
- Time
- Measured 1 hour after a single dose
fear extinction in claustrophobia and PTSD therapy (off-label)
- Effect
- Mixed; helped only when therapy sessions went well, and possibly harmful when they did not
- Best fit
- Adults in exposure-based therapy within a research setting
- Time
- Measured 1 to 3 months after brief therapy
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
Alzheimer's disease (LMTM, a related compound, not methylene blue itself)
No benefit foundNot an approved use, and not methylene blue itself: this trial tested LMTM, a related compound. In a 15-month phase 3 trial in 891 people with mild to moderate Alzheimer's disease in 16 countries, LMTM (a stable reduced form of methylthioninium, the active part of methylene blue) at 75 mg or 125 mg twice daily did not slow decline on either main measure of memory and thinking or daily function compared with a control dose of 4 mg twice daily. An earlier phase 2 trial of methylthioninium chloride (methylene blue) in 321 people suggested benefit at 138 mg a day, and a 2026 phase 3 trial of hydromethylthionine could not show differences on its main measures at 52 weeks (the authors attributed this to effects in the control group), reporting differences in mild cognitive impairment only at 78 and 104 weeks. The 15-month phase 3 trial was funded by the developer, TauRx Therapeutics.
Bottom line: The largest completed trial of LMTM, a compound related to methylene blue, did not slow Alzheimer's disease.
Evidence is mixed
A phase 2 trial of methylthioninium chloride reported benefit at 138 mg a day, and a 2026 phase 3 trial of hydromethylthionine reported late differences in mild cognitive impairment, but the coprimary outcomes of the large phase 3 trials were not met at their prespecified time points.
bipolar depression, added to other treatment (off-label)
Disease adjunctOff-label use. In a 6-month double-blind crossover trial, 37 people with bipolar disorder already taking lamotrigine received methylene blue 195 mg a day or a 15 mg comparison dose. The higher dose improved depression scores (MADRS, P = 0.02) and anxiety scores (P = 0.02), mania stayed low, and cognitive test results did not improve. A 1986 two-year crossover trial in 31 people on lithium (17 completed) found less depression on 300 mg a day than on 15 mg, but the authors noted many dropouts and doubts about blinding.
Bottom line: Two small trials suggest an add-on effect on bipolar depression; it has not been confirmed or approved.
delirium after surgery in older adults (off-label, intravenous)
Disease adjunctOff-label use, given intravenously in an operating room, not by mouth. In a randomized trial of 217 adults aged 60 or older having joint replacement, an infusion of 2 mg/kg methylene blue during anesthesia lowered delirium in the 5 days after surgery from 20.4% to 8.3% (hazard ratio 0.39). Fever after surgery was more common with methylene blue (16.5% vs 7.4%).
Bottom line: One trial found an intravenous dose during surgery cut post-operative delirium; it says nothing about oral supplements.
memory and attention in healthy adults (off-label)
Biomarker supportOff-label use. In a double-blind, placebo-controlled trial, 26 healthy adults aged 22 to 62 had brain scans (functional MRI) during attention and short-term memory tasks before and 1 hour after a single low dose of methylene blue by mouth or placebo. Methylene blue increased brain activity in several regions during the tasks and was associated with a 7% increase in correct answers during memory retrieval. It was one dose, in one small group, measured once; it did not test daily use, the products sold online, or any long-term outcome.
Bottom line: One small single-dose study hints at a short-term memory effect; it is far from proof of a brain supplement.
fear extinction in claustrophobia and PTSD therapy (off-label)
Disease adjunctOff-label use. In 42 adults with marked claustrophobia, a single 260 mg dose of methylene blue after an exposure session led to less fear a month later only in those whose fear had dropped during the session; those still very afraid at the end tended to do worse than with placebo. In a trial of 42 people with chronic PTSD, 260 mg was given after 5 daily imaginal exposure sessions. Both the methylene blue and placebo groups improved strongly and did not differ from standard prolonged exposure therapy at 3 months, although methylene blue improved evaluator-rated treatment response and quality of life compared with placebo.
Bottom line: Small studies give mixed results, with a possible downside after unsuccessful therapy sessions.
How it works
How to take it
What to track
Bottom line: An intravenous hospital treatment at 1 mg/kg set by your prescriber; there is no approved oral dose, and serotonergic medicines and G6PD deficiency are the key dangers.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Serotonin syndrome with serotonergic drugs and opioids (boxed warning): ProvayBlue may cause serious or fatal serotonin syndrome when used with SSRIs, SNRIs, MAOIs and opioids, and the label says to avoid these combinations. Symptoms include agitation, hallucinations, fast heartbeat, swings in blood pressure, sweating, fever, tremor, muscle rigidity or jerks, seizures, nausea and diarrhea. A published case report described serotonin syndrome after starting an oral urinary product containing methylene blue in a person taking several serotonergic drugs, so the risk is not limited to intravenous use.
Severe hemolytic anemia in G6PD deficiency: methylene blue is contraindicated in G6PD deficiency, where it may cause severe hemolysis and severe anemia and may not work. Hemolysis can also occur in people without G6PD deficiency, and the anemia may appear a day or more after treatment and may need transfusion.
Severe allergic reactions, including anaphylaxis, angioedema, hives and bronchospasm, have been reported with methylene blue products.
Misleading oxygen readings: methylene blue in the blood can make a pulse oximeter underestimate oxygen saturation, and it can lower the Bispectral Index used to monitor anesthesia depth.
Unapproved oral products: every methylene blue product approved in Drugs@FDA is an intravenous solution such as ProvayBlue, so drops, capsules and powders sold for swallowing are not FDA-approved drugs and FDA has not reviewed their strength, purity or dose. Older urinary antiseptic tablets that contain methylene blue are listed on DailyMed as "unapproved drug other".
Who should avoid it
- People with G6PD deficiency (contraindicated because of the risk of hemolytic anemia)
- People who have had a severe allergic reaction to methylene blue or any other thiazine dye (contraindicated)
- People taking serotonergic medicines (SSRIs, SNRIs, MAOIs, bupropion, buspirone, clomipramine, mirtazapine, linezolid) or opioids or dextromethorphan, unless their care team decides intravenous treatment cannot be avoided
- People with moderate or severe kidney impairment or any liver impairment need extra care rather than avoidance (this is not a contraindication): the label gives a single 1 mg/kg dose in moderate or severe kidney impairment, because levels rise, and longer monitoring with any liver impairment, because clearance is delayed
Pregnancy & breastfeeding
Pregnancy: the ProvayBlue label says it may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Injection of a methylene blue product into the amniotic fluid during the second trimester was associated with intestinal atresia (a blocked bowel) in newborns and fetal death, and methylene blue given by mouth to pregnant rats and rabbits caused harm to the developing young. After injection into the amniotic fluid near birth, or treatment of a pregnant woman at term, the newborn should be watched for jaundice, hemolytic anemia, methemoglobinemia, breathing problems and light sensitivity. Breastfeeding: there is no information on whether methylene blue passes into human milk; because of possible serious effects, including damage to genetic material, the label says to stop breastfeeding during treatment and for up to 8 days afterward.
Interactions
Boxed warning: methylene blue appears to block MAO, and with these antidepressants it has caused serotonin syndrome, sometimes fatal. The label says to avoid the combination; if intravenous treatment cannot be avoided, the lowest dose is used and the person is watched closely for up to 4 hours. Never take an oral methylene blue product with these medicines; your prescriber decides how your antidepressant is handled.
The boxed warning names opioids: methylene blue may cause serious or fatal serotonin syndrome with them, and the label says to avoid the combination. Tell every prescriber and pharmacist if you use methylene blue in any form.
The label names these among medicines that enhance serotonin transmission and says to avoid using them with methylene blue because of the potential for serious nervous system reactions, including potentially fatal serotonin syndrome; it also says dextromethorphan may increase the risk. Linezolid is an antibiotic that also blocks MAO. Check cough and cold products with your pharmacist, and ask your prescriber or pharmacist before combining anything with methylene blue.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is oral methylene blue FDA-approved as a supplement?⌄
No. Every methylene blue product approved in Drugs@FDA is an injection given into a vein, such as ProvayBlue, used for methemoglobinemia. The drops, capsules and powders sold online for focus, energy or longevity are not FDA-approved drugs, and their strength and purity have not been reviewed by FDA.
Does methylene blue improve memory or brain function?⌄
The evidence is thin. One trial in 26 healthy adults found a single dose by mouth changed brain-scan activity and gave 7% more correct answers on a memory task an hour later. Small trials in bipolar depression found less depression and anxiety, but no improvement on cognitive tests. A large trial of a related drug did not slow Alzheimer's disease. No trial has tested the products sold online or long-term daily use.
Can I take methylene blue with my antidepressant?⌄
The label carries a boxed warning against using it with SSRIs, SNRIs and MAOIs, because methylene blue can cause serious or fatal serotonin syndrome with them. The label also says to avoid bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids and dextromethorphan with it. Do not combine an oral methylene blue product with these, and do not stop or change your antidepressant on your own: talk with your prescriber or pharmacist.
Why does G6PD deficiency matter?⌄
Methylene blue needs an NADPH-dependent enzyme to work, and people with G6PD deficiency make less NADPH in their red blood cells. The label says methylene blue is contraindicated in G6PD deficiency because it can cause severe hemolysis and severe anemia, and it may not even work. Ask your doctor whether you have been tested, especially if it runs in your family.
Can I take methylene blue with my supplements?⌄
Our interaction database has no supplement pairs for methylene blue yet, so this page lists only the medicine interactions from the label. Because the label warns about anything that enhances serotonin transmission, have a doctor or pharmacist review every supplement and medicine you take before any use.
Why did my urine turn blue?⌄
Methylene blue is a dye that passes into the urine, so blue or blue-green urine is expected. The label notes it can interfere with urine tests that rely on a blue indicator, and it can make pulse oximeter readings look lower than they are. Tell anyone testing you that you have had methylene blue.
References by claim
memory and attention in healthy adults (off-label)
Rodriguez et al., 2016 · PMC (2016) link
bipolar depression, added to other treatment (off-label)
fear extinction in claustrophobia and PTSD therapy (off-label)
Alzheimer's disease (LMTM, a related compound, not methylene blue itself)
delirium after surgery in older adults (off-label, intravenous)
Zhang et al., 2025 · PMC (2025) link
Track Methylene Blue with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
